Smartlab Europe

News

Quotient Sciences Invests in Drug Substance Manufacturing Facility

Quotient Sciences, a drug development and manufacturing company, is investing £6.3 million pounds ($8.6mn) in its recently acquired manufacturing facility in Alnwick, UK. The investment will expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over...

Innovent Biologics, Bolt Biotherapeutics Enter Immuno oncology Alliance

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for cancer, metabolic, autoimmune and other diseases, and Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents, entered a collaboration to research...

SK bioscience & GSK initiate phase 3 trial of adjuvanted Covid-19 vaccine candidate

SK bioscience (SK) and GlaxoSmithKline (GSK) announced the initiation of a phase 3 clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim phase 1/2 results. The randomised, active-controlled global trial will enroll...

Abbott introduces single-dose formulation of carbetocin for prevention of postpartum haemorrhage in India

Abbott, the global healthcare company has announced the introduction of a room-temperature-stable, single-dose formulation of carbetocin in India, which is available in convenient vials, to help in the prevention of postpartum haemorrhage (PPH). Abbott’s product is available in the...

Drug Substance Freezing and Why It Doesn’t Have To Be a Bottleneck

Drug substance freezing has moved on. Traditionally it was inefficient in a multitude of ways. Issues such as product loss, reduction of product potency, or a lack of flow with the surrounding processes such bulk filling, storage and shipping were...

Rapid Development and Industrialization of a COVID-19 Viral Vector Vaccine Manufacturing Process

The year 2020 will go down in history books as a year that changed the world and helped drug manufacturing to evolve. When the COVID-19 pandemic began at the start of the year, vaccine production was less of an...

Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia

Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on "Non-clinical and clinical pathways for rapid vaccine development in Australia", in a webinar hosted by Endpoints...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »